Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride lowers blood glucose by decreasing hepatic gluconeogenesis and increasing peripheral insulin sensitivity. Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4, which prolongs the activity of incretin hormones (GLP‑1 and GIP). This leads to glucose‑dependent insulin release and reduced glucagon secretion, complementing metformin’s effects for a synergistic reduction in plasma glucose.

The dose of Jansitin Duo is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Physicians determine the appropriate strength and dosing schedule, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Safety of Jansitin Duo in pregnancy and lactation has not been established. The product should be avoided unless the potential benefits outweigh the risks, and the decision should be made by a qualified healthcare provider after a thorough assessment of maternal and fetal health.

To order Jansitin Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Jansitin Duo offers a fixed‑dose combination of metformin and a DPP‑4 inhibitor, providing a convenient oral regimen that avoids the weight gain associated with sulfonylureas and the injection requirement of GLP‑1 receptor agonists. Compared with metformin alone, the addition of sitagliptin yields greater HbA1c reduction, while maintaining a relatively low risk of hypoglycemia.

Store Jansitin Duo at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use. Do not store in the refrigerator or freezer.

Jansitin Duo is taken orally as a tablet. It may be swallowed with or without food, according to the prescriber’s guidance. Patients should follow the dosing schedule prescribed by their healthcare professional and should not crush or chew the tablet unless specifically instructed.

The most serious adverse reactions to watch for are lactic acidosis, which can be life‑threatening, and acute pancreatitis. Additionally, severe hypoglycemia may occur when Jansitin Duo is combined with insulin or sulfonylureas. Prompt medical attention is required if any of these conditions are suspected.

Jansitin Duo is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hepatic disease, a history of lactic acidosis, or hypersensitivity to metformin, sitagliptin, or any excipients. It should also be avoided in pregnancy and lactation unless the prescriber determines that the benefits outweigh the risks.